Compare DexCom, Inc. (DXCM) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Synchrony Financial — how do they compare? DexCom, Inc. trades at $83.7 (market cap $31.86B), while Synchrony Financial trades at $72.82 (market cap $23.99B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Synchrony Financial pays a 1.84% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Synchrony Financial for 28 Days on average.
| DXCM | SYF | |
|---|---|---|
Market Cap | $31.86B | $23.99B |
Volume | 3,607,070 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $92.34 | $88.47 |
52-Week Low | $54.84 | $63.78 |
Typical Hold Time | 62 Days | 28 Days |
Enterprise Value | $31.32B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Synchrony Financial (SYF) trades at $73.16, up 1.71% on the day, with a bullish technical signal despite some bearish moving averages. The stock shows strong fundamentals, with a low P/E of 7.56 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten expectations, and the company is expanding through partnerships like the recent tie-up with Vetspire and OpenAI.
The outlook is positive, supported by analyst consensus with a $87.58 price target and 61% buy ratings. Key opportunities include high receivables growth and strategic AI integrations, while risks involve increased investing cash outflows and potential consumer credit stress amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
